REduced Frequency ImmuNE checkpoint inhibition in cancers
Is less frequent dosing of immunotherapy drugs as effective but more convenient for patients and hospitals?
What is this study about?
REFINE is a clinical trial for patients who are receiving immune checkpoint inhibitors for the treatment of advanced cancers. These drugs work by stimulating the body’s own immune system to fight against cancer cells. Immune checkpoint inhibitors can stop cancers from growing for many months or years.
Immune checkpoint inhibitors are given to patients through an injection into a vein every 3-6 weeks in a hospital or clinic. Blood tests are needed before each injection. This means that patients spend a lot of time (and money) on hospital visits.
Clinical trials have proven the effectiveness of immune checkpoint inhibitors in the treatment of different cancers. However, the best way to give these drugs is not known. It is likely that immune checkpoint inhibitors work for a longer period of time than originally thought. This means it may be possible to give the drugs less often and still have the same effect on the cancer. The REFINE trial tests whether giving an immunotherapy drug less often to patients with advanced cancer results in fewer side effects and improved quality of life, whilst continuing to be an effective treatment. Giving these drugs less often may also allow the NHS to deliver equally effective treatment at a lower cost.
Type of study
Who is funding the study?
The trial is funded by the Jon Moulton Charity Trust.
When is it taking place?
The trial opened in 2022 and is currently recruiting participants.
Where is it taking place?
UK NHS sites.
Who is included?
Adults with advanced cancer being treated with immune checkpoint inhibitors in the UK.
REFINE trials opens their melanoma cohort
19 Apr 2023
REFINE trial recruits its first participant
22 Aug 2022